Clínica Baviera, S.A. (CBAV.MC)
EUR 34.0
(0.0%)
EUR 34.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 57.85 Million | 53.37 Million | 46.85 Million | 31.45 Million | 25.4 Million | 16.81 Million |
| Net Income | 35.97 Million | 40.67 Million | 38.89 Million | 20.18 Million | 17.78 Million | 16.8 Million |
| Depreciation & Amortization | 16.98 Million | 14.99 Million | 14.09 Million | 13.54 Million | 13.22 Million | 4.96 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 1.75 Million | 4.96 Million | 3.83 Million | 2.39 Million | -2.11 Million | -625.15 Thousand |
| Other non-cash items | 3.14 Million | -7.26 Million | -9.97 Million | -4.67 Million | -3.49 Million | -4.33 Million |
| Investing Cash Flow | -44.46 Million | -12.55 Million | -17.08 Million | -21.4 Million | -6.67 Million | -9.11 Million |
| Investments in PPE | -22.67 Million | -14.03 Million | -10.57 Million | -7.81 Million | -9.19 Million | -9.4 Million |
| Acquisitions | -536 Thousand | - | -50 Thousand | - | -905.96 Thousand | -1.32 Million |
| Investment purchases | -40.53 Million | -24.51 Million | -10.5 Million | -13.59 Million | -21.91 Thousand | -1.04 Million |
| Sales/Maturities of investments | 18.74 Million | 25.92 Million | 4.04 Million | 383.00 | 3.43 Million | 1.33 Million |
| Other Investing Activities | 536 Thousand | 67.21 Thousand | 3191.00 | 8005.00 | 1806.00 | 1.33 Million |
| Financing Cash Flow | -24.25 Million | -31.44 Million | -30.79 Million | -3.15 Million | -18.71 Million | -9.46 Million |
| Debt repayment | -2 Million | -6.05 Million | -5.77 Million | -5.9 Million | -6.48 Million | -7.87 Million |
| Dividends payments | -13.04 Million | -17.18 Million | -17.34 Million | - | -9.45 Million | -7.82 Million |
| Common Stock Repurchased | -706.49 Thousand | -617.39 Thousand | -491.37 Thousand | -190.68 Thousand | -206.17 Thousand | -133.94 Thousand |
| Common Stock Issuance | 711.12 Thousand | 596.93 Thousand | 503.3 Thousand | 196.42 Thousand | 136.37 Thousand | 76.94 Thousand |
| Other Financing Activities | -703.19 Thousand | -8.18 Million | -7.68 Million | 5.63 Million | -2.5 Million | 6.39 Million |
| Accounts receivables | -433.43 Thousand | 176.39 Thousand | - | 555.67 Thousand | -1.57 Million | 261.85 Thousand |
| Accounts payables | 2.5 Million | 5.01 Million | - | 2.28 Million | -412.21 Thousand | -840.4 Thousand |
| Inventory | -311.92 Thousand | -228.57 Thousand | -291.42 Thousand | -443.32 Thousand | -136.13 Thousand | -46.6 Thousand |
| Other working capital | 2.5 Million | - | 4.12 Million | - | - | -578.55 Thousand |
| Cash at beginning of period | 19.17 Million | 9.8 Million | 10.82 Million | 3.92 Million | 3.91 Million | 5.67 Million |
| Cash at end of period | 8.3 Million | 19.17 Million | 9.8 Million | 10.82 Million | 3.92 Million | 3.91 Million |
| Capital Expenditure | -22.67 Million | -14.03 Million | -10.57 Million | -7.81 Million | -9.19 Million | -9.4 Million |
| Effect of forex changes on cash | 19.28 Million | - | - | - | - | - |
| Net cash flow / Change in cash | -10.86 Million | 9.37 Million | -1.02 Million | 6.9 Million | 10.37 Thousand | -1.76 Million |
| Free Cash Flow | 35.17 Million | 39.34 Million | 36.28 Million | 23.63 Million | 16.21 Million | 7.4 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 15.71 Million | 16.77 Million | 13.12 Million | 35.97 Million | 7.4 Million | 13.37 Million |
| Depreciation & Amortization | 5.05 Million | 4.57 Million | 4.62 Million | 16.98 Million | 4.31 Million | 4.12 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 726 Thousand | -725 Thousand | 3.08 Million | 1.75 Million | 1.71 Million | -576 Thousand |
| Other non-cash items | 2.62 Million | 13.17 Million | -4.93 Million | 3.14 Million | -1.12 Million | - |
| Investing Cash Flow | -17.33 Million | -6.8 Million | -30.38 Million | -44.46 Million | 5.08 Million | -15.81 Million |
| Investments in PPE | -6.4 Million | -6.78 Million | -8.51 Million | -22.67 Million | -5.74 Million | -5.22 Million |
| Acquisitions | - | - | - | -536 Thousand | - | - |
| Investment purchases | - | - | - | -40.53 Million | - | - |
| Sales/Maturities of investments | - | - | - | 18.74 Million | - | - |
| Other Investing Activities | -10.74 Million | -15 Thousand | -21.86 Million | 536 Thousand | 10.82 Million | - |
| Financing Cash Flow | -12.58 Million | -2.85 Million | -2.57 Million | -24.25 Million | -3 Million | -16.24 Million |
| Debt repayment | - | -501 Thousand | -502.32 Thousand | -2 Million | -328 Thousand | -676 Thousand |
| Dividends payments | - | - | -33.52 Thousand | -13.04 Million | -168 Thousand | - |
| Common Stock Repurchased | -4.72 Million | - | - | -706.49 Thousand | - | - |
| Common Stock Issuance | - | - | - | 711.12 Thousand | - | - |
| Other Financing Activities | -5.54 Million | -113 Thousand | - | -703.19 Thousand | -2.5 Million | -4.15 Million |
| Accounts receivables | - | - | - | -433.43 Thousand | - | - |
| Accounts payables | - | - | - | 2.5 Million | - | - |
| Inventory | - | - | - | -311.92 Thousand | - | - |
| Other working capital | 500.00 | - | - | - | - | - |
| Cash at beginning of period | - | - | - | 19.17 Million | - | - |
| Cash at end of period | -11.91 Million | 10.63 Million | -17.06 Million | 8.3 Million | 14.38 Million | -19.36 Million |
| Capital Expenditure | -6.4 Million | -6.78 Million | -8.51 Million | -22.67 Million | -5.74 Million | -5.22 Million |
| Effect of forex changes on cash | - | - | - | 19.28 Million | - | - |
| Net cash flow / Change in cash | -11.91 Million | 10.63 Million | -17.06 Million | -10.86 Million | 14.38 Million | -19.36 Million |
| Free Cash Flow | 11.6 Million | 13.5 Million | 7.38 Million | 35.17 Million | 6.56 Million | 7.47 Million |
002492
SGGKF
RFLXF
000595
ARR
DMF